TECH

Bivacor Medical Set to Go Public on NYSE: A New Era in Cardiac Care

Bivacor Medical, a pioneering company in the field of cardiovascular innovation, is set to officially go public on the New York Stock Exchange (NYSE) this December 15th. The company plans to issue 100,000,000 shares at an initial price of $18 per share, marking a significant milestone in its growth journey.

A Transformative Moment

In anticipation of this landmark event, Bivacor Medical is excited to announce that 15% of its shares are currently available for presale, priced between $3.20 and $5.00. This presale offers an exclusive opportunity for early investors to engage with a company dedicated to revolutionizing cardiac care through cutting-edge technology.

Statement from the Founder

Dr. Daniel Timms, CTO of Bivacor, expressed enthusiasm about the upcoming IPO, stating: “Going public is a transformative moment for Bivacor Medical. It allows us to raise the capital needed to accelerate our growth and innovation. We are committed to developing advanced medical devices that significantly improve patient outcomes, and this IPO will enable us to reach more patients in need.”

Dr. Timms continued, “The presale of shares is a unique opportunity for investors to join us on this journey at an attractive price point. We believe that our groundbreaking technology, including the Bivacor Total Artificial Heart, positions us for substantial growth in the rapidly evolving healthcare market.”

A Commitment to Innovation

Bivacor Medical has garnered attention for its flagship product, the Bivacor Total Artificial Heart, which represents a significant advancement in the treatment of severe heart failure. The company’s mission is to enhance the quality of life for patients suffering from cardiovascular diseases through innovative solutions and rigorous clinical testing.

Looking Ahead

The IPO is expected to attract significant interest from both institutional and retail investors, reflecting the growing confidence in Bivacor Medical’s potential for success in the healthcare sector. With the funds raised from the IPO, the company plans to invest in research and development, expand its product offerings, and enhance its market presence.

Investors interested in participating in the presale or learning more about Bivacor Medical's public offering can visit the company’s website for additional details.

As Bivacor Medical prepares for its debut on the NYSE, the company stands at the forefront of innovation in cardiac care. With a strong commitment to improving patient outcomes and a clear vision for the future, Bivacor.

PUBLISHED WED, OCT 11 20244:17 PM EDT

Ashley Capoot

@IN/ASHLEY-CAPOOT-02496B173

KEY POINTS

IPO Announcement: Bivacor Medical is set to go public on the NYSE on December 15, 2024, issuing 100,000,000 shares at an initial price of $18 per share, with 15% available for presale priced between $3.30 and $5.00.
Founders's Vision: Dr. [Daniel Timms emphasizes that going public will enable Bivacor to accelerate growth and innovation, particularly in developing advanced medical devices like the Bivacor Total Artificial Heart, aimed at improving patient outcomes.
Investment Opportunity: The upcoming IPO is expected to attract significant interest from investors, reflecting confidence in Bivacor Medical's potential for success in the healthcare sector and its commitment to enhancing cardiac care solutions.